Please read and agree to the terms and conditions of this site.
@xconomy.com 3 years ago
FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats
@xconomy.com 3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com 4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com 4 years ago
Amgen’s Osteoporosis Drug Wins European Nod, With a Heart Warning
@xconomy.com 4 years ago
Disc Medicine Launches With $50M to Advance New Anemia Treatments
@xconomy.com 4 years ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing
@xconomy.com 4 years ago
Chasing Blueprint, Deciphera Plans FDA Filing for GI Cancer Drug
@xconomy.com 5 years ago
New Data Puts Aldeyra One Step Closer to FDA Filing for Eye Drug
@xconomy.com 5 years ago
FDA OKs Depression Drug For New Moms: Fast Relief But Tough to Take
@xconomy.com 5 years ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug
@xconomy.com 5 years ago
Editas CEO Katrine Bosley to Depart on Cusp of CRISPR Clinical Trial
@xconomy.com 5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com 5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com 5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com 5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com 5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
@xconomy.com 5 years ago
Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug
@xconomy.com 6 years ago
Fixing the Clinical Trial Bottleneck by Making Patients a Priority
@xconomy.com 6 years ago
OncoNano, Maker of Tumor Imaging Technology, Raises $11.7 Million
@superglaze 7 years ago
RT @oliviasolon: As the FDA approves phase 3 trials of MDMA, here's how it could become a prescription medicine for PTSD https://t.co/JFp214Jnvp